deoxyuridine has been researched along with Carcinoma, Non-Small Cell Lung in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Boellaard, R; Frings, V; Giovannetti, E; Herder, GJ; Hoekstra, OS; Honeywell, R; Peters, GJ; Smit, EF; Thunnissen, E; van der Veldt, AA | 1 |
Dantzig, AH; Donoho, GP; Durland-Busbice, S; Perkins, EJ; Pratt, SE; Shepard, RL; Starling, JJ; Wickremsinhe, ER | 1 |
Clarke, SJ; Li, KM; Rivory, LP | 1 |
1 trial(s) available for deoxyuridine and Carcinoma, Non-Small Cell Lung
Article | Year |
---|---|
Pemetrexed pharmacokinetics and pharmacodynamics in a phase I/II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedules.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Deoxyuridine; Dietary Supplements; Dose-Response Relationship, Drug; Female; Folic Acid; Glutamates; Guanine; Homocysteine; Humans; Lung Neoplasms; Male; Methylmalonic Acid; Middle Aged; Pemetrexed; Thymidine; Thymidylate Synthase; Vinblastine; Vinorelbine; Vitamin B 12 | 2007 |
2 other study(ies) available for deoxyuridine and Carcinoma, Non-Small Cell Lung
Article | Year |
---|---|
Pemetrexed induced thymidylate synthase inhibition in non-small cell lung cancer patients: a pilot study with 3'-deoxy-3'-[¹⁸F]fluorothymidine positron emission tomography.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxyuridine; Dideoxynucleosides; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Neoplasm Metastasis; Outcome Assessment, Health Care; Pemetrexed; Polymorphism, Genetic; Positron-Emission Tomography; Prognosis; Thymidylate Synthase; Time Factors; Tissue Distribution | 2013 |
Efficacy of low-dose oral metronomic dosing of the prodrug of gemcitabine, LY2334737, in human tumor xenografts.
Topics: Administration, Metronomic; Administration, Oral; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Deoxyuridine; Disease Models, Animal; Dose-Response Relationship, Drug; Gemcitabine; Gene Expression; HCT116 Cells; Humans; Lung Neoplasms; Mice; Prodrugs; Valproic Acid; Xenograft Model Antitumor Assays | 2013 |